Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | February 17, 2023 | February 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date February 17, 2023 · Filed February 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 4,235 |
Reported balance
After 2023-02-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-17 · Grant · Acquired 1,500 · Balance 4,235 F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.
F2: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2023 Filed Feb 22, 2023 19:15 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011926 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,235 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010377 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,822 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:05 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017573 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,822 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 15, 2020, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-55. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 19:27 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 225,000 | $0.10 | $22,500.00 |
DisclosureSEC source: 0001209191-19-057497 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,841 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 20:41 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | Tax withholdingCommon stock, $0.0001 par value | 1,751 | $0.40 | $705.65 |
DisclosureSEC source: 0001209191-19-044370 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,841 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 09:24 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 152,415 | $0.38 | $57,887.22 |
DisclosureSEC source: 0001209191-19-014816 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,592 F1 · kind: As reported on the Current Report on Form 8-K filed on February 15, 2019, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on February 28, 2019, the reporting person received a total of 152,415 shares of common stock from the Company in lieu of $57,887 of cash compensation, which includes a portion of the reporting person's deferred annual bonus for 2018 that was payable on such date. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 08:54 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 22,279 | $0.36 | $8,096.19 |
DisclosureSEC source: 0001209191-19-010898 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,177 F1 · kind: As reported on the Current Report on Form 8-K filed on February 15, 2019, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on February 15, 2019, the reporting person received a total of 22,279 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 11:16 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $0.0001 par value | 21,470 | $0.38 | $8,096.34 |
DisclosureSEC source: 0001209191-19-006663 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,898 F1 · kind: As reported on the Current Report on Form 8-K filed on September 4, 2018 and December 21, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on February 1, 2019, the reporting person received a total of 21,470 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 10:25 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 23,729 | $0.34 | $8,096.33 |
DisclosureSEC source: 0001209191-19-004688 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,428 F1 · kind: As reported on the Current Report on Form 8-K filed on September 4, 2018 and December 21, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on January 18, 2019, the reporting person received a total of 23,729 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 09:14 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 23,139 | $0.35 | $8,096.34 |
DisclosureSEC source: 0001209191-19-002394 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,699 F1 · kind: As reported on the Current Report on Form 8-K filed on September 4, 2018 and December 21, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on January 4, 2019, the reporting person received a total of 23,139 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 09:20 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 27,445 | $0.30 | $8,096.28 |
DisclosureSEC source: 0001209191-18-064049 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,560 F1 · kind: As reported on a Current Report on Form 8-K filed on September 4, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on December 21, 2018, the reporting person received a total of 27,445 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| December 07, 2018 Filed Dec 10, 2018 09:34 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 21,882 | $0.37 | $8,096.34 |
DisclosureSEC source: 0001209191-18-061677 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,115 F1 · kind: As reported on a Current Report on Form 8-K filed on September 4, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on December 7, 2018, the reporting person received a total of 21,882 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| November 23, 2018 Filed Nov 26, 2018 09:29 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon stock, $0.0001 par value | 25,941 | $0.31 | $8,096.19 |
DisclosureSEC source: 0001209191-18-059875 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,233 F1 · kind: As reported on a Current Report on Form 8-K filed on September 4, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on November 23, 2018, the reporting person received a total of 25,941 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 09:24 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 18,698 | $0.43 | $8,096.23 |
DisclosureSEC source: 0001209191-18-058091 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,292 F1 · kind: As reported on a Current Report on Form 8-K filed on September 4, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on November 9, 2018, the reporting person received a total of 18,698 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| October 26, 2018 Filed Oct 29, 2018 09:26 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 18,519 | $0.44 | $8,096.51 |
DisclosureSEC source: 0001209191-18-056341 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,594 F1 · kind: As reported on a Current Report on Form 8-K filed on September 4, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on October 26, 2018, the reporting person received a total of 18,519 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 09:24 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 17,230 | $0.47 | $8,096.38 |
DisclosureSEC source: 0001209191-18-054919 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,075 F1 · kind: As reported on a Current Report on Form 8-K filed on September 4, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on October 12, 2018, the reporting person received a total of 17,230 shares of common stock from the Company in lieu of $8,096.16 of cash compensation, which includes base salary, that was payable on such date. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 12:40 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 73,587 | $1.17 | $86,096.79 |
DisclosureSEC source: 0001209191-18-052657 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,845 F1 · kind: As reported on a Current Report on Form 8-K filed on September 4, 2018, the reporting person has elected to receive a portion of his compensation in stock in lieu of cash. Accordingly, on September 28, 2018, the reporting person received a total of 73,587 shares of common stock from the Company in lieu of $86,096.16 of cash compensation that was payable on such date, which includes base salary and a portion of the reporting person's deferred annual bonus for 2017, which was paid on September 28, 2018. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:29 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 21,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-045456 · doc4.xml · derivative · entry 3 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common stock · 21,000 shares Expires 2028-08-01 F2 · derivative.exercise_date: The stock option will vest in four equal annual installments. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:29 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045456 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,258 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 15:44 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 7,100 | $0.45 | $3,195.00 |
DisclosureSEC source: 0001209191-17-054555 · doc4.xml · nonDerivative · entry 3 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,583 Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 15:44 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 200 | $0.46 | $92.00 |
DisclosureSEC source: 0001209191-17-054555 · doc4.xml · nonDerivative · entry 2 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,483 Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 15:44 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,700 | $0.44 | $1,188.00 |
DisclosureSEC source: 0001209191-17-054555 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,283 Read SEC document |
| August 24, 2017 Filed Aug 24, 2017 11:55 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 739 | $0.56 | $413.84 |
DisclosureSEC source: 0001209191-17-050044 · doc4.xml · nonDerivative · entry 3 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,583 Read SEC document |
| August 24, 2017 Filed Aug 24, 2017 11:55 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 4,361 | $0.55 | $2,398.55 |
DisclosureSEC source: 0001209191-17-050044 · doc4.xml · nonDerivative · entry 2 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,844 Read SEC document |
| August 24, 2017 Filed Aug 24, 2017 11:55 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 4,900 | $0.55 | $2,670.50 |
DisclosureSEC source: 0001209191-17-050044 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,483 Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 11:49 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 5,000 | $0.62 | $3,100.00 |
DisclosureSEC source: 0001209191-17-041289 · doc4.xml · nonDerivative · entry 2 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,583 Read SEC document |
| June 22, 2017 Filed Jun 22, 2017 11:49 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 5,000 | $0.63 | $3,150.00 |
DisclosureSEC source: 0001209191-17-041289 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,583 Read SEC document |
| April 26, 2017 Filed Apr 26, 2017 10:52 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 10,000 | $0.65 | $6,480.00 |
DisclosureSEC source: 0001209191-17-028187 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,583 Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 09:16 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 15 | $0.77 | $11.48 |
DisclosureSEC source: 0001209191-17-021599 · doc4.xml · nonDerivative · entry 3 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,583 Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 09:16 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 665 | $0.77 | $508.79 |
DisclosureSEC source: 0001209191-17-021599 · doc4.xml · nonDerivative · entry 2 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,568 Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 09:16 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 9,320 | $0.77 | $7,171.74 |
DisclosureSEC source: 0001209191-17-021599 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,903 Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 07:11 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 2,917 | $0.70 | $2,027.32 |
DisclosureSEC source: 0001209191-17-012427 · doc4.xml · nonDerivative · entry 3 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,583 Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 07:11 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 6,883 | $0.69 | $4,765.79 |
DisclosureSEC source: 0001209191-17-012427 · doc4.xml · nonDerivative · entry 2 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,666 Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 07:11 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 200 | $0.69 | $138.30 |
DisclosureSEC source: 0001209191-17-012427 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,783 Read SEC document |
| February 08, 2017 Filed Feb 8, 2017 11:43 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 10,000 | $0.69 | $6,850.00 |
DisclosureSEC source: 0001209191-17-008542 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,583 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:14 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-17-007720 · doc4.xml · derivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-02-01 F1 · derivative.exercise_date: The stock option vests in a one-quarter installment on the one year anniversary of the grant date and in monthly installments thereafter over the remaining three years. Read SEC document |
| January 25, 2017 Filed Jan 26, 2017 08:05 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 9,700 | $0.70 | $6,758.96 |
DisclosureSEC source: 0001209191-17-005642 · doc4.xml · nonDerivative · entry 2 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,583 Read SEC document |
| January 25, 2017 Filed Jan 26, 2017 08:05 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 300 | $0.69 | $207.00 |
DisclosureSEC source: 0001209191-17-005642 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,883 Read SEC document |
| January 19, 2017 Filed Jan 19, 2017 13:48 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 600 | $0.69 | $416.94 |
DisclosureSEC source: 0001209191-17-004383 · doc4.xml · nonDerivative · entry 3 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,583 Read SEC document |
| January 19, 2017 Filed Jan 19, 2017 13:48 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 3,000 | $0.69 | $2,083.80 |
DisclosureSEC source: 0001209191-17-004383 · doc4.xml · nonDerivative · entry 2 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,983 Read SEC document |
| January 19, 2017 Filed Jan 19, 2017 13:48 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | PurchaseCommon stock, $0.0001 par value | 6,400 | $0.70 | $4,448.00 |
DisclosureSEC source: 0001209191-17-004383 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,983 Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 06:39 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 2,000 | $0.73 | $1,452.00 |
DisclosureSEC source: 0001209191-17-000003 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,583 Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 06:43 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 3,000 | $0.72 | $2,157.00 |
DisclosureSEC source: 0001209191-16-156732 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 4,500 Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 06:12 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 3,000 | $0.75 | $2,247.00 |
DisclosureSEC source: 0001209191-16-156612 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,583 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:33 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock warrant · Derivative | 33,333 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-16-156238 · doc4.xml · derivative · entry 4 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common stock · 33,333 shares Expires 2021-12-21 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:33 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | GrantCommon stock, $0.0001 par value | 33,333 | $0.90 | $29,999.70 |
DisclosureSEC source: 0001209191-16-156238 · doc4.xml · nonDerivative · entry 1 CAUWENBERGH GEERT · CIK 0001285648 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,583 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.